Antibiotic stability over six weeks in aqueous solution at body temperature with and without heat treatment that mimics the curing of bone cement. by Samara, E. et al.
vol. 6, No. 5, May 2017 296
Freely available online open  Access
BJR
Article focus
  Comprehensive data describing thermal 
stability of antibiotic agents in aqueous 
solution at physiological temperature for 
local application in orthopaedic indica-
tions are not available.
  Thermal stability at 37°C of 37 antibiotic 
drugs over six weeks is described.
  as bone cement is frequently used in 
orthopaedic surgery for the local delivery 
of antibiotics, the potential effect of the 
exothermic curing process of bone 
cement on antibiotic agents was also 
examined.
Key messages
  aminoglycosides, glycopeptides, tetracy-
clines and quinolones have good thermal 
stability over six weeks, but local toxicity 
issues might limit local application of tet-
racyclines and quinolones.
  While beta-lactams show exponential 
degradation over time, sustained antibac-
terial activity can be observed for up to 
Antibiotic stability over six weeks in 
aqueous solution at body temperature 
with and without heat treatment that 
mimics the curing of bone cement
Objectives
Thermal stability is a key property in determining the suitability of an antibiotic agent for 
local application in the treatment of orthopaedic infections. Despite the fact that long-term 
therapy is a stated goal of novel local delivery carriers, data describing thermal stability over 
a long period are scarce, and studies that avoid interference from specific carrier materials 
are absent from the orthopaedic literature.
Methods
In this study, a total of 38 frequently used antibiotic agents were maintained at 37°c in 
saline solution, and degradation and antibacterial activity assessed over six weeks. The 
impact of an initial supplementary heat exposure mimicking exothermically curing bone 
cement was also tested as this material is commonly used as a local delivery vehicle. Anti-
biotic degradation was assessed by liquid chromatography coupled to mass spectrometry, 
or by immunoassays, as appropriate. Antibacterial activity over time was determined by the 
Kirby-Bauer disk diffusion assay.
Results
The heat exposure mimicking curing bone cement had minimal effect on stability for most 
antibiotics, except for gentamicin which experienced approximately 25% degradation as 
measured by immunoassay. Beta-lactam antibiotics were found to degrade quite rapidly at 
37°c regardless of whether there was an initial heat exposure. excellent long-term stability 
was observed for aminoglycosides, glycopeptides, tetracyclines and quinolones under both 
conditions.
Conclusions
This study provides a valuable dataset for orthopaedic surgeons considering local applica-
tion of antibiotics, and for material scientists looking to develop next-generation controlled 
or extended-release antibiotic carriers.
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three weeks, with aztreonam displaying even greater 
stability.
  The heat generated by curing bone cement does not 
have any effect on the majority of the antibiotic agents 
tested, except for gentamicin, that degraded by 
approximately 25%.
strengths and limitations
  Two analytical methods have been used: qualitative 
assessment of antimicrobial activity by disk diffusion 
tests; and quantification by liquid chromatography 
coupled to mass spectrometry, or fluorescence polar-
isation immunoassays, as available.
   Degradation half-lives have been calculated from 
quantification data, but these methods were available 
for only 20 antibiotics.
  antibacterial activity has been tested by the Kirby-
Bauer disk diffusion assay, but interpretation of inhibi-
tion zone results has limitations, particularly as some 
substances have inconstant diffusion or degradation 
on agar.
Introduction
local delivery of antibiotics enables high drug concentra-
tions to be achieved at the desired site of antimicrobial 
action, while keeping systemic exposure and toxicity 
low.1-3 The following characteristics are desirable for a 
given antimicrobial agent to be suitable for local applica-
tion: adequate antimicrobial spectrum; chemical com-
patibility with, and adequate release kinetics from the 
chosen carrier; appropriate solubility; low local toxicity; 
low systemic exposure and/or toxicity; and low risk of 
hypersensitivity.1-5 Thermal stability is a key factor in 
determining an antibiotic’s suitability for local applica-
tion, as it must not only resist any heat generated during 
the manufacturing process of the carrier, but also be sta-
ble at body temperature over the entire duration of the 
release period inside the patient.2,4 Despite the growing 
use of locally delivered antimicrobial agents, data regard-
ing thermal stability in such settings are incomplete, 
scarce or even lacking entirely.
a large number of studies have been published that 
examine drug release in vitro and in vivo from various car-
rier materials.3,5-9 However, these studies primarily tested 
compatibility with carrier substances and were designed 
to quantify the amount of antibiotic released from the 
matrix. The most commonly tested condition is antibiotic 
release from bone cement (polymethyl methacrylate, 
PMMa), which has been shown to release antibiotic over 
a number of weeks.6 However, such data are specific to 
the formulation of the bone cement and do not translate 
to other materials. overall, the limited data available at 
present have studied antibiotic stability over a short 
period of time and below body temperature or with a 
restricted range of antibiotics.10 Such studies have 
generally been performed with the purpose of testing 
portable infusion devices for prolonged intravenous anti-
biotic therapy in an outpatient setting, for continuous 
antibiotic infusion to optimise antimicrobial pharmaco-
dynamics in critical care, or for the use of antibiotics in 
peritoneal dialysis solution.11-16 Information regarding 
thermal stability of antibiotics exposed to body tempera-
ture over a prolonged period is thus necessary for a com-
prehensive assessment of the suitability of their use for 
local application.
The primary aim of this study was therefore to exam-
ine the stability of solutions of 38 antibiotics maintained 
at 37°C for six weeks, a common duration of treatment 
in the orthopaedic setting.17,18 Such data are critical for 
any future controlled extended release antibiotic deliv-
ery vehicle. as PMMa remains the most frequently used 
carrier material in orthopaedic applications,3-5 the sec-
ondary objective of this study was to examine the impact 
of an initial thermal treatment simulating the exothermic 
process of PMMa polymerisation, followed by exposure 
to 37°C for six weeks, on antibiotic stability. This study 
will therefore provide an overview of the thermal stabil-
ity of a broad range of antibiotics, helping to guide clini-
cians in selecting the most appropriate agents for local 
application.
Materials and Methods
Antibiotic agents. antibiotic agents were selected on the 
basis of clinical experience in local application, published 
experimental data, and potential for local application 
based on chemical properties and antimicrobial mode of 
action. Preference was given to clinically available anti-
biotic preparations, rather than analytical or research 
preparations. Solutions were used only if no powdered 
form was available. a total of 38 antibiotic agents were 
included, five of which were combination products. 
The combination products involved either two partner 
antibiotics or one antibiotic with an enzyme inhibitor. 
In the case of combination products, only the antibiotic 
agent(s) for which an analytical methodology was avail-
able were measured. a comprehensive list is provided in 
Table I. Each antibiotic was dissolved or diluted in 0.9 % 
w/v NaCl (B. Braun Medical, Sempach, Switzerland) to 
an arbitrary initial target concentration of 200 mg/l. The 
prepared solutions, therefore, contained the antibiotic 
drug as well as any excipients present in the pharmaceu-
tical formulations. Details of preservatives and excipients 
present in the antibiotic may be found, where present, 
on the package inserts. antibiotics were generally avail-
able as salt, and less frequently as base or acid. Each 
antibiotic solution was divided into two equal portions 
immediately after preparation. one portion was directly 
incubated at 37°C for 42 days (Regular group) and the 
second exposed to a thermal curve mimicking the exo-
thermic bone cement curing process (as described 
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below), followed by incubation at 37°C for 42 days (Heat 
group). aliquots of the antibiotic solution were taken 
after preparation, and again after 12 and 24 hours, and 
at two, three, five, seven, 14, 21 and 42 days. at each 
time point, triplicate 1 ml aliquots were withdrawn and 
frozen in cryotubes (Thermo Fisher Scientific (Schweiz), 
Reinach, Switzerland), and stored at -80°C until analysis. 
Samples were analysed as a single batch upon comple-
tion of the study.
Temperature monitoring and exposure: determination of 
temperature-time profile during PMMA polymerisation. a 
40 g package of commercially available high viscosity 
bone cement (Palacos R; Heraeus Medical, Wehrheim, 
Germany) was prepared according to manufacturer 
instructions using manual mixing. The cement dough was 
then poured into a 60 ml syringe. a thermocouple sensor 
(Type K Thermocouple; Pico Technology, Eaton Socon, 
United Kingdom) was inserted 5 mm into the cement, 
and the second sensor recorded ambient air tempera-
ture. after 12 minutes, when the cement had hardened, 
the syringe was removed and the cement block, with 
the thermocouple still in place, was immersed in a water 
bath at 37°C (Sonorex Super; Bandelin electronic, Berlin, 
Germany) to mimic the positioning of a formed cement 
spacer in the human body. Cement and water tempera-
ture were measured at 15 second intervals (recorded by 
Table I. list of tested antibiotics and corresponding methods for measuring drug concentration and antimicrobial activity
Antibiotic Brand name (supplier) Quantification Disk Diffusion
Penicillins  
amoxicillin Clamoxyl (GlaxoSmithKline, Münchenbuchsee, Switzerland) lC-MS/MS S. aureus NCTC 12973
amoxicillin+clavulanate Co-amoxi-Mepha (Mepha Pharma, Basel, Switzerland) S. aureus NCTC 12973
Flucloxacillin Floxapen (actavis, Regensdorf, Switzerland) lC-MS/MS S. aureus NCTC 12973
Ticarcillin+clavulanate Timentin (GlaxoSmithKline, Brentford, United Kingdom) S. aureus NCTC 12973
Temocillin Negaban (Eumedica, Manage, Belgium) E. coli NCTC 12241
Piperacillin+tazobactam Piperacillin Tazobactam (Sandoz Pharmaceuticals, Risch-Rotkreuz, 
Switzerland)
lC-MS/MS S. aureus NCTC 12973
Cephalosporins  
Cefazolin Kefzol (Teva Pharma, Basel, Switzerland) lC-MS/MS S. aureus NCTC 12973
Cefuroxime Zinacef (GlaxoSmithKline, Münchenbuchsee, Switzerland) lC-MS/MS S. aureus NCTC 12973
Cefotaxime Claforan (Sanofi-aventis, vernier, Switzerland) S. aureus NCTC 12973
Ceftriaxone Rocephin (Roche Pharma, Reinach, Switzerland) lC-MS/MS S. aureus NCTC 12973
Ceftazidime Fortam (GlaxoSmithKline, Münchenbuchsee, Switzerland) lC-MS/MS S. aureus NCTC 12973
Cefepime Cefepime orPha (orPha Swiss, Küsnacht, Switzerland) lC-MS/MS S. aureus NCTC 12973
Carbapenems and monobactams  
Imipenem+cilastatin Imipenem-Cilastatin labatec (labatec Pharma, Meyrin, Switzerland) lC-MS/MS S. aureus NCTC 12973
Meropenem Meropenem labatec (labatec Pharma, Meyrin, Switzerland) lC-MS/MS S. aureus NCTC 12973
Ertapenem Invanz (Merck & Co, lucerne, Switzerland) lC-MS/MS S. aureus NCTC 12973
aztreonam azactam (Bristol-Myers Squibb, Cham, Switzerland) E. coli NCTC 12241
Glycopeptides and lipopeptides  
vancomycin vancocin (Teva Pharma, Basel, Switzerland) lC-MS/MS S. aureus NCTC 12973
Teicoplanin Teicoplanin labatec (labatec Pharma, Meyrin, Switzerland) S. aureus NCTC 12973
Telavancin vibativ (Theravance, San Francisco, California) S. aureus NCTC 12973
Daptomycin Cubicin (Novartis Pharma, Basel, Switzerland) lC-MS/MS S. aureus NCTC 12973
Aminoglycosides  
amikacin amikin (Bristol-Myers Squibb, Cham, Switzerland) FPIa S. aureus NCTC 12973
Gentamicin Gentamicin-MP (InfectoPharm, Heppenheim, Germany) FPIa S. aureus NCTC 12973
Tobramycin obracin (Teva Pharma, Basel, Switzerland) FPIa S. aureus NCTC 12973
Quinolones  
Ciprofloxacin Ciproxine (Bayer, Zürich, Switzerland) lC-MS/MS S. aureus NCTC 12973
levofloxacin Tavanic (Sanofi-aventis, vernier, Switzerland) lC-MS/MS S. aureus NCTC 12973
Moxifloxacin avalox (Bayer, Zürich, Switzerland) S. aureus NCTC 12973
Macrolides and ketolides  
Erythromycin Erythrocine (Pro Concepta, Zug, Switzerland) S. aureus NCTC 12973
Clarithromycin Klacid (abbott, Baar, Switzerland) S. aureus NCTC 12973
azithromycin Zithromax (Pfizer, Zürich, Switzerland) S. aureus NCTC 12973
Telithromycin Ketek (Sanofi-aventis, vernier, Switzerland) S. aureus NCTC 12973
Tetracyclines and glycylcyclines  
Doxycycline vibravenös (Pfizer, Zürich, Switzerland) S. aureus NCTC 12973
Minocycline Minac (Spirig Pharma, Egerkingen, Switzerland) S. aureus NCTC 12973
Various  
Rifampin Rimactan (Sandoz Pharmaceuticals, Risch, Switzerland) lC-MS/MS S. aureus NCTC 12973
Clindamycin Clindamycin (Sandoz) lC-MS/MS S. aureus NCTC 12973
linezolid Zyvoxid (Pfizer, Zürich, Switzerland) lC-MS/MS S. aureus NCTC 12973
Fusidic acid Fucidin (leo Pharmaceuticals, Regensdorf-Watt, Switzerland) S. aureus NCTC 12973
Trimethoprim with sulfamethoxazole Bactrim (Roche Pharma, Reinach, Switzerland) S. aureus NCTC 12973
Colistimethate Colistin (Forest laboratories, Zürich, Switzerland) lC-MS/MS P. aeruginosa Pao1
lC-MS/MS, High-performance liquid chromatography coupled to tandem mass spectrometry; FPIa, fluorescence polarisation immunoassay; DD, disk diffu-
sion; NCTC, national collection of type cultures.
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USB TC-08 Thermocouple Data logger and Picolog data 
acquisition, Pico Technology). The experiment was per-
formed in triplicate.
Temperature monitoring and exposure : heat exposure 
mimicking PMMA polymerisation. a steam autoclave 
(vitaris, Münchenstein, Switzerland) was used to subject 
test solutions to a heat programme that would mimic 
the observed temperature-time profile of curing cement. 
Glass bottles containing 150 ml of antibiotic solution 
were placed in the pre-warmed autoclave. Temperature 
monitoring in the liquid was performed through a ther-
mocouple sensor directly immersed in 0.9% NaCl solu-
tion, with measurements recorded every 15 seconds. 
once a maximum chamber temperature of 83°C had 
been reached and maintained for 60 seconds, the solu-
tions were removed and exposed to ambient air for three 
minutes. Subsequently, the bottles were immersed in a 
water bath at 17°C. Temperatures were recorded every 
15 seconds from commencement of the heat cycle until 
the temperature of 37°C was reached. The water bath was 
set to 17°C in order to accept the heat transfer from the 
antibiotic solution-containing bottles, and still achieve 
the target of 37°C within a time-frame closely matching 
curing PMMa. The target chamber temperature of 83°C 
was set so that the solution may exceed this temperature, 
but still not reach boiling point. The above-described 
heat cycle has been chosen to follow as closely as pos-
sible the heat-time profile of curing PMMa, without caus-
ing the test solutions to boil.
Assessment of antibiotic concentration and activity: high 
performance liquid chromatography coupled to tandem 
mass spectrometry. The concentrations of 19 antibiotic 
agents were measured by high-performance liquid chro-
matography coupled to tandem mass spectrometry (lC-
MS/MS) using adaptations of validated methods used in 
therapeutic drug monitoring in patients, or by specifi-
cally developing lC-MS/MS assays for this project (Table 
I). antibiotic drug concentrations were determined from 
samples, thawed and analysed as a single batch after 
appropriate dilution of aliquots, collected at 0 hour and 
at days one, three, seven and 42. Reverse-phase chro-
matographic separation of antibiotics was obtained using 
stepwise gradient elution of the mobile phase, consisting 
of 10 mM ammonium formate solution with 0.4% formic 
acid and acetonitrile delivered onto a 1.8 µm UPlC col-
umn Waters acquity UPlC HSS T3 2.1 x 50 mm (Waters 
Corp., Milford, Massachusetts).
Detection was performed by electrospray ionisation–
triple quadrupole mass spectrometry on Quantum mass 
spectrometers (Thermo Fisher Scientific, Waltham, 
Massachusetts), by selected reaction monitoring detec-
tion, using the specific antibiotic transitions in the positive 
mode, except for cefuroxime (negative mode, as cefurox-
ime is negatively charged after ionisation). antibiotic 
quantification was performed using matrix-matched 
calibration samples using the stable isotopically labelled 
internal standard of each antibiotic (except for vancomy-
cin, for which no labelled internal standard was available 
and therefore an external calibration was applied). The 
lower limits of quantification (loQ) range from 0.02 mg/l 
to 1 mg/l. Individual loQ limits were 0.02 mg/l for 
rifampin, 0.05 mg/l for cefazolin, cefepime, imipenem, 
meropenem, tazobactam, and colistin, 0.08 mg/l for 
piperacillin, 0.1 mg/l for amoxicillin, flucloxacillin, cefuro-
xime, ceftazidime, ertapenem, ciprofloxacin, levofloxacin, 
clindamycin, and linezolid, 0.5 mg/l for ceftriaxone and 
daptomycin, and 1 mg/l for vancomycin.
Assessment of antibiotic concentration and activity: fluo-
rescence polarisation immunoassays. The concentrations 
of gentamicin, tobramycin and amikacin were measured 
by fluorescence polarisation immunoassay (FPIa) on a 
Cobas Integra 400 plus (Roche Diagnostics International, 
Rotkreuz, Switzerland) using the standard reagents of the 
commercial kit. appropriate dilution of test solutions was 
performed with human plasma since immunoassays can 
only be performed in the same biological matrix that is 
used for calibration. The loQ was 0.5 mg/l, 0.74 mg/l 
and 2.5 mg/l for gentamicin, tobramycin and amikacin, 
respectively.
Assessment of antibiotic concentration and activity: disk 
diffusion test. antimicrobial activity of all antibiotic solu-
tions was measured by the Kirby-Bauer disk diffusion 
method, performed following the European Committee 
on antimicrobial Susceptibility Testing (EUCaST) proto-
col.19,20 Reference strains E. coli NCTC 12241, P. aeru-
ginosa Pao1, or S. aureus NCTC 12973, were chosen 
depending on the spectrum of activity of the antibiotic 
tested, and are shown in Table I. Samples were tested 
in triplicate using 7 mm paper disks (Becton Dickinson, 
Heidelberg, Germany), impregnated with 20 µl sample 
solution. The disks were placed on circular Petri dishes 
with 25 ml Mueller Hinton agar (Thermo Fisher Scientific 
oxoid ltd, Basingstoke, United Kingdom), which was 
inoculated with a suspension of the reference organism. 
Each test batch included a control disk containing 10 µg 
gentamicin (Becton Dickinson) to ascertain proper prep-
aration and application of the bacterial suspension. Plates 
were incubated at 37°C for 20 hours, at which time zones 
of inhibition (ZoI) were measured to the nearest whole 
millimetre.
Data analysis. Mean values and standard deviations have 
been calculated from triplicate samples, for the results 
from lC-MS/MS, FPIa, and also disk diffusion assays. 
The results of lC-MS/MS or FPIa quantifications were 
expressed as a percentage of the initial concentration, 
i.e. without the initial heat exposure. a two-way aNova 
was used to compare differences between the regular 
and body temperature groups for the lC-MS/MS data. 
Sidak's post hoc test was used to control for multiple 
comparisons. The results from the disk diffusion tests are 
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indicated as diameter of the zone of inhibition. a two-
way aNova was used to compare differences between 
the ZoI diameter over time. In all cases, significance was 
accepted at p < 0.05. Prism software was used for all 
statistical tests (GraphPad Software, la Jolla, California). 
The in vitro half-lives (t1/2) of the antibiotics measured 
using lC-MS/MS were calculated as ln2/ke, considering 
the terminal slope of the decay, where ke is (ln Cday7 –  
ln Cday42)/(Tday42 – Tday 7).
Results
Determination of temperature-time profile during PMMA 
polymerisation. The temperature-time profiles of curing 
PMMa and the heat exposure programme applied to 
the antibiotic solutions are shown in Figure 1. For cur-
ing PMMa, the time required from initial mixing until 
equilibration with the 37°C water bath was 22 minutes. 
The highest temperature measured during this time 
was 111.7°C. The replication of the temperature-time 
curve for the antibiotic solutions also lasted 22 minutes, 
although the peak temperature was lower (90.7°C) in 
order to prevent the aqueous solutions from boiling.
Quantification by LC-Ms/Ms and FPIA. The concentration 
of the antibiotics determined by lC-MS/MS and FPIa, plot-
ted against time, are summarised in Figure 2 for both the 
regular and the heat groups. Statistically significant differ-
ences between both groups have been marked in Figure 2. 
only gentamicin showed a drop in concentration of about 
25% due to the initial heat treatment, but remained stable 
thereafter. Results for clindamycin have been eliminated 
because the original antibiotic solution apparently decom-
posed during storage and no drug or degradation product 
could be measured.
Assessment of antibacterial activity by disk diffusion 
test. ZoI sizes determined by the disk diffusion tests 
are illustrated for all antibiotic agents in Figure 3. again, 
clindamycin was inactive, suggestive of drug decomposi-
tion during storage, and thus not reported. The differ-
ence in ZoI between the regular and the heat groups 
were usually within 1 mm to 2 mm, and thus only 
results from the regular group are illustrated graphically. 
Statistically significant differences have been marked in 
the figure, where appropriate. The only antibiotics that 
showed a significant reduction of ZoI by 3 mm to 4 mm 
in the heat group as compared with the body tempera-
ture group were amoxicillin with clavulanate (but not 
amoxicillin alone), cefazolin, cefuroxime, cefotaxime, cef-
triaxone and ertapenem, but these differences were only 
noticeable on day one. Both curves thereafter were virtu-
ally identical. Daptomycin showed a marked variability of 
ZoI over time, which can be explained in part by the lim-
ited reliability of the bioassay method for this antibiotic.
Calculation of degradation half-life in vitro. Degradation 
half-life values calculated from lC-MS/MS and FPIa data 
are given in Table II. When the variability in concentra-
tions was within the analytical variability with profiles 
essentially parallel to the x-axis, the antibiotic was consid-
ered to be stable and marked as such without indicating 
calculated values. Since no significant differences have 
been observed between the regular and the heat groups, 
calculations have been performed with results from the 
regular group only.
Discussion
Thermal stability is a key feature in determining whether a 
given antibiotic is suitable for local application.2,4 The pre-
sent study provides a comprehensive dataset on the ther-
mal stability of 37 antibiotic agents, monitored over six 
weeks - a duration which may be targeted for future local 
antibiotic delivery, as it generally corresponds to the stand-
ard duration of treatment of bone and implant-associated 
infections.17,18 The potentially deleterious impact on 
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circles with black error bars), to which antibiotic solutions were exposed. Measurements were taken every 15 seconds, data represent mean results of a triplicate 
and error bars represent standard deviation.
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antibiotic integrity of the initial heat released during the 
curing of PMMa, the carrier material used most commonly 
in orthopaedic and trauma surgery,3-5 has also been 
examined as a secondary, additional outcome relevant to 
current clinical practice. Results from this study were 
focused on applications in orthopaedics, but may also find 
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Fig 2
Thermal stability determined for each antibiotic over time as measured by lC-MS/MS or FPIa. antibiotic solutions were prepared and maintained at 37°C for 
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Fig. 3a
Charts showing thermal stability measured for each antibiotic over time, as determined by bioassay. Results are expressed as means from triplicate experi-
ments. Zone of inhibition (ZoI) indicates diameter of the zone of inhibition, in millimetres. Statistically significant variations of the ZoI relative to starting 
values are marked with an asterisk where appropriate. antibiotic solutions were prepared and maintained at 37°C for 42 days (body temperature group). 
of note, temocillin and aztreonam have been tested with E. coli NCTC 12241, and colistimethate with P. aeruginosa Pao1, whereas all other results are from 
inhibition of S. aureus NCTC 12973.
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Fig. 3b
Charts showing thermal stability measured for each antibiotic over time, as determined by bioassay. Results are expressed as means from triplicate experi-
ments. Zone of inhibition (ZoI) indicates diameter of the zone of inhibition, in millimetres. Statistically significant variations of the ZoI relative to starting 
values are marked with an asterisk where appropriate. antibiotic solutions were prepared and maintained at 37°C for 42 days (body temperature group). 
of note, temocillin and aztreonam have been tested with E. coli NCTC 12241, and colistimethate with P. aeruginosa Pao1, whereas all other results are from 
inhibition of S. aureus NCTC 12973.
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applications in other clinical settings wherein antibiotic 
stability is also an issue, such as administration of antibiot-
ics by continuous infusion or via portable elastomeric 
pumps for parenteral outpatient treatment.11-16,21 The lat-
ter example certainly is an issue since portable devices 
might reach temperatures of up to 35°C under real-life 
conditions.21
overall, large differences in antibiotic stability have 
been observed, ranging from rapid degradation of antibi-
otics within one to two weeks, to almost complete stability 
over the entire six-week test period. Not unexpectedly, 
beta-lactam antibiotics were found to be almost com-
pletely degraded over time, with the exception of the 
monobactam aztreonam, which apparently has a higher 
stability.16,21,22 Some beta-lactams, namely flucloxacillin, 
ticarcillin with clavulanate, piperacillin with tazobactam, 
cefazolin and ceftriaxone, maintained relevant antibacte-
rial activity for up to 21 days. The greater inhibition zones 
observed in the bioassays for the combination of amoxicil-
lin with clavulanate, compared with amoxicillin alone, 
might be explained by a synergistic antibacterial effect of 
the combination.23,24 on the other hand, clavulanate is 
known to catalyse the degradation of amoxicillin in aque-
ous solution.25 However, this has not been quantified in 
our experiment. Temocillin has been reported to yield 
promising results for the treatment of outpatients using 
continuous perfusion pumps,13 but performed poorly in 
our study, showing a rapid decay of the antimicrobial 
activity measured by the Kirby-Bauer assay. Excellent 
long-term stability has been confirmed in our study for 
aminoglycosides and glycopeptides, strengthening their 
suitability and use in the orthopaedic setting.3-5,14,22 
Tetracyclines and quinolones were highly thermo-stable 
according to our study but may not be acceptable for local 
application due to their reported cellular toxicity.26,27 
linezolid, trimethoprim with sulfamethoxazole, and, to a 
lesser extent, fusidic acid, all appeared to have good stabil-
ity, without known relevant toxicity at the concentrations 
tested.27 Rifampin, while being a cornerstone in the treat-
ment of implant-associated Staphylococci infections17 
showed a rapid decrease of antibacterial activity after two 
weeks, as measured by bioassay.
our investigations indicate that the initial short-term 
temperature elevation mimicking curing of PMMa has 
limited, if any, impact on antibiotic stability overall. 
Gentamicin was the only drug that was found to be 
affected to some extent, with a reduction of about 25% 
caused by the initial heat treatment. This was not 
observed for the other aminoglycosides tested. For van-
comycin and colistimethate, significant discrepancies 
were observed in the heat group between the mass spec-
trometry quantification and bioassay. The prodrug colis-
timethate needs to be hydrolysed to yield the active 
colistin, and the extent of such a reaction in the disk diffu-
sion test is uncertain, while the poor diffusion of the 
active colistin on agar also limits interpretability of the 
bioassay results, even if colistin resistance can be identi-
fied quite reliably with this method.28 For vancomycin, 
possible changes in the solution’s matrix after the initial 
heat treatment may potentially diminish antibiotic bioa-
vailability via alteration of the antibiotic adsorption onto 
the paper disk and diffusion, hence diminishing the anti-
microbial activity.
The quantification of lC-MS/MS and FPIa provides pre-
cise drug concentrations, and allows us to determine the 
in vitro degradation half-lives (Table II). However, such 
methods were not available for all antibiotics, notably the 
macrolides/ketolides and the tetracyclines/glycylcyclines 
(Table I). Disk diffusion tests have been used for a qualita-
tive, rather than quantitative, assessment of activity for 
these antibiotics. The establishment of calibration curves 
to enable semi-quantitative measurement of such a large 
number of antibiotics would have been technically chal-
lenging, relatively imprecise, and interpretation would 
have been limited to narrow ranges of concentrations.29 
Besides, for glycopeptides and daptomycin, the disk 
Table II. In vitro degradation half-lives, calculated from quantitative data by 
lC-MS/MS and FPIa as available from the body temperature group
Antibiotic drugs t1/2 h (days)
Penicillins  
amoxicillin 150 (6.3)
Flucloxacillin 381 (15.9)
Piperacillin 410 (17.1)
Tazobactam 619 (25.8)
Cephalosporins  
Cefazolin 265 (11.0)
Cefuroxime 81 (3.4)
Ceftriaxone 261 (10.9)
Ceftazidime 176 (7.3)
Cefepime 115 (4.8)
Carbapenems and monobactams  
Imipenem 72 (3.0)
Cilastatin 3202 (133.4)
Meropenem 67 (2.8)
Ertapenem 96 (4.0)
Glycopeptides and lipopeptides  
vancomycin Stable
Daptomycin 945 (39.4)
Aminoglycosides  
amikacin Stable
Gentamicin Stable
Tobramycin Stable
Quinolones  
Ciprofloxacin Stable
levofloxacin Stable
Various  
Rifampicin 95 (4.0)
linezolid Stable
Colistimethate Stable
t1/2, half-life
There was no significant difference between samples subjected and those 
not subjected to the initial heat exposure. “Stable“ indicates a degradation 
below the limit of detection, that is, the observed variability was smaller than 
the known analytical variability. after a degradation of about 25% induced 
by the initial short-term heat treatment, gentamicin remains stable (see 
Fig. 2). Cilastatin is a renal dehydropeptidase inhibitor co-administered to 
imipenem.
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diffusion approach can be used only for ascertaining the 
presence of antibacterial activity.20,30 More generally, the 
comparison with recommended breakpoints for suscepti-
bility testing using bioassays is also limited since, for most 
antibiotics in our experiment, quantities that have to be 
loaded onto paper disks would exceed the starting con-
centration, which had been defined in consideration of 
local toxicity issues.19,20,27,30
a strength of this study is that two different analytical 
approaches have been used. Precise quantification of the 
most commonly prescribed antibiotic agents has been 
performed by lC-MS/MS or FPIa, while antibacterial activ-
ity has been ascertained for all antibiotics by disk diffusion 
assays. overall, the bioassays were generally congruent 
with the quantitative analysis by lC-MS/MS or FPIa. The 
lC-MS/MS method reveals that gentamicin was in part 
degraded by the initial heat treatment, while this 25% 
drop in concentration could not be detected by the less 
sensitive disk diffusion assay. Thus, tobramycin might be a 
more appropriate antibiotic to associate with PMMa, as it 
has an equivalent spectrum of activity31 but improved sta-
bility in our experiment. of course, tissue penetration is 
an additional factor in the performance of any antibiotic, 
be it locally or systemically applied, even if difficult to 
interpret.32,33 Data on antibiotic penetration of tobramy-
cin versus gentamicin are limited,32 but the expectation 
would be that it would be similar due to very similar phys-
icochemical properties.34 Even if all assays had been per-
formed as a batch at the end of the experiment, no 
degradation of the antibiotics during storage would be 
expected, even for the more fragile beta-lactams, as the 
samples have been kept continuously at -80°C.35
limitations of our experimental setting have to be 
acknowledged, particularly regarding the heat exposure 
mimicking the exothermic process taking place during 
the curing of bone cement. The temperature profile 
recorded in our study is specific to a given cement and 
form. Cements with other specifications and other quan-
tities and forms may yield different temperature-time 
profiles.36 The experimental design, i.e. subjecting an 
aqueous solution to a steam autoclave, may not have 
reproduced a temperature-time profile that strictly fol-
lowed the one observed during the solid-state cement 
curing as boiling of the test solution had to be avoided. 
The use of pressure-resistant closed containers might 
allow testing of the potential effect of higher tempera-
tures, but these were not available for the required vol-
umes. While no discrepancies were observed between 
lC-MS/MS or FPIa and disk diffusion tests, disk diffusion 
data are available for more time points within the study 
period, while quantification assays suffer from a gap 
between day seven and day 42. The schedule had been 
chosen to adapt best to exponential degradation of 
unstable drugs, while still being able to describe long-
term stability. The results, however, do not indicate that 
a certain degradation profile would not have been 
detected. another issue could be the fact that a number 
of antibiotics were tested in combination, however, the 
effects of these combinations cannot be evaluated as the 
individual drugs were not tested in isolation. last, but not 
least, the test samples were solutions of antibiotics, also 
containing the various components of the pharmaceuti-
cal preparations such as preservatives, buffers and stabi-
lising agents that reflect only partially the interactions 
with biological solutions and the various reactions occur-
ring during cement curing.
In conclusion, our study provides information of inter-
est not only for local application of antibiotics in ortho-
paedic and trauma surgery, but also in other medical 
specialties that require prolonged antibiotic exposure 
and for which drug stability is also an issue. In order to 
maximise the applicability of our data, we did not test 
elution from any material, or measure degradation at 
room or refrigerated temperatures. our experiments 
have allowed the identification of classes of antibiotics or 
specific agents deemed useful for further investigation 
because of favourable in vitro stability. additionally, this 
dataset is relevant for the next generation of antibiotic 
carriers as it provides data pertinent to the thermal stabil-
ity of a range of antibiotics that may be considered for 
this use. Nevertheless, any future studies on antibiotic 
carriers should include careful assessment of antibiotic 
release kinetics, both in vitro and in vivo.
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